Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

(2014) Terence O'Reilly et al.   Translational Oncology

Surgical resection of subependymal giant cell astrocytomas (SEGAs) and changes in SEGA-related conditions: a US national claims database study

(2012) Peter Sun et al.   CURRENT MEDICAL RESEARCH AND OPINION

Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis

(2012) Peter Sun et al.   CURRENT MEDICAL RESEARCH AND OPINION

Everolimus alters white matter diffusion in tuberous sclerosis complex

(2012) J.-M. Tillema et al.   NEUROLOGY

Ovarian Toxicity from Sirolimus

(2012) Matthias Braun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex

(2011) Marta Perek-Polnik et al.   EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY

Research and innovation in the development of everolimus for oncology

(2011) David Lebwohl et al.   Expert Opinion on Drug Discovery

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Tuberous Sclerosis Complex: Neurological, Renal and Pulmonary Manifestations

(2011) D. N. Franz et al.   NEUROPEDIATRICS

Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex

(2010) Michal Yalon et al.   CHILDS NERVOUS SYSTEM

Tuberous sclerosis complex: tumors and tumorigenesis

(2010) Julita Borkowska et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

(2010) Darcy A. Krueger et al.   NEW ENGLAND JOURNAL OF MEDICINE

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature

(2009) M. E. A. P. M. Adriaensen et al.   EUROPEAN JOURNAL OF NEUROLOGY

Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis

(2009) Kristen Pollizzi et al.   Molecular Cancer

The TSC1–TSC2 complex: a molecular switchboard controlling cell growth

(2008) Jingxiang Huang et al.   BIOCHEMICAL JOURNAL

Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex

(2008) Mary Kay Koenig et al.   JOURNAL OF CHILD NEUROLOGY

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data

(2008) Chiaki Tanaka et al.   JOURNAL OF CLINICAL ONCOLOGY

Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function

(2008) L. Meikle et al.   JOURNAL OF NEUROSCIENCE

Tuberous sclerosis

(2008) Paolo Curatolo et al.   LANCET

Possible mechanisms of disease development in tuberous sclerosis

(2008) Jaroslaw Jozwiak et al.   LANCET ONCOLOGY

Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study

(2008) Anna M. Buccoliero et al.   NEUROPATHOLOGY